| First author, year [ref.] | Population studied | Cases n | Detection methods | Tumour enrichment strategy | Primary tumour/metastatic tumour | Rate showing discordance | |||
| Mutant /mutant | WT/WT | Mutant/WT | WT/mutant | ||||||
| Sun, 2011 [35] | Surgically resected NSCLC | 80 pairs of PT/LNM | DS | Macrodissection | 26.3 | 67.5 | 0 | 6.3 | 8.8# |
| Chang, 2011 [36] | Surgically resected NSCLC | 56 pairs of PT/LNM | DS | Macrodissection | 19.6 | 51.8 | 21.5 | 7.1 | 28.6 |
| Park, 2009 [37] | Surgically resected NSCLC | 101 pairs of PT/LNM | DS HDA | Microdissection | 10 (by DS) 18.8 (by HDA) | 78.2 (by DS) 64.4 (by HDA) | 10.9 (by DS) 9.9 (by HDA) | 1 (by DS) 6.9 (by HDA) | 11.9 (by DS) 16.8 (by HDA) |
| Yatabe, 2011 [22] | Lung adenocarcinoma with LNM | 77 pairs of EGFR+ PT/LNM | Cycleave PCR/FA | NA | 100 | 0 | 0 | 0 | 0 |
| 50 pairs of EGFR- PT/LNM | 0 | 100 | 0 | 0 | 0 | ||||
| Chen, 2012 [32] | Patients with tumour samples available from ≥2 disease sites | 84 | DS/HRMA | NA | NA | NA | NA | NA | 14.3 in paired PT/DM 10.2 in paired PT/LNM |
| Kalikaki, 2008 [38] | NSCLC and corresponding metastasis | 25 pairs of PT/DM | DS | Microdissection | 4 | 72 | 16 | 8 | 28 |
| Gow, 2009 [39] | 67 pairs of PT/DM | DS/SARMS | NA | 13.4 | 47.8 | 13.4 | 25.4 | 38.8 (27 by SAMS) | |
Data are presented as %, unless otherwise stated. EGFR: epidermal growth factor receptor; WT: wild-type; NSCLC: nonsmall cell lung cancer; PT: primary tumour; LNM: lymph node metastasis; DS: direct Sanger sequencing; HDA: heteroduplex analysis; FA: fragment analysis; NA: not available; HRMA: high resolution melting analysis; DM: distant metastasis; SARMS: scorpion amplified refractory mutation system. #: two cases among 80 pairs demonstrated different mutational profiles of EGFR.